Análisis de la acción Mineralys Therapeutics Inc (MLYS)MLYSMineralys Therapeutics Inc

Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and with hypertension and OSA. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Mineralys Therapeutics Inc (MLYS) is not a strong buy due to its significant recent losses and negative technical indicators. The stock is trading at $20.55, which is down 42.45% year-to-date and 49.33% over the past year. The RSI is at 36.371, indicating it is nearing oversold territory, but the MACD shows a bearish trend with a value of -1.431. The company has posted substantial losses, with a net income of -241 million in Q2 2026, and a forward P/E ratio of 0 suggests uncertainty in future earnings. The main risk is the company's declining equity, which dropped to $550 million in Q2 2026 from $646 million in Q4 2025. Given these factors, it may be prudent to hold off on buying until there are clearer signs of recovery and improved financial performance.